Pave the road to successful commercialization of your radiopharmaceutical innovation with CARI – The CPDC & adMare Radiopharmaceutical Initiative

October 6, 2020 CPDC

If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020.

What is CARI?

CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) where we will bring respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain considerable global competitive advantage: RADIOPHARMACEUTICALS. The objective of CARI, is for CPDC and adMare to seek out and uncover radiopharmaceutical opportunities arising from academic discoveries and early enterprises, establish rigorous drug development programs around selected opportunities, and drive the generation of proof-of-principle and other data supportive of the commercialization of new radiopharmaceutical assets.

Have more questions about CARI? Then you don’t want to miss this Webinar!

Please kindly register before Wednesday, Oct. 14th – click here to register.

More news from CPDC

CPDC Announces Appointment of Bruno Paquin as Permanent CEO

Hamilton, Ontario (March 10, 2021) – The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Bruno Paquin as Chief Executive Officer (CEO). The CEO appointment has taken effect on March 4, 2021. Dr. John Thornback, Chair of the Board of Directors said, “We are pleased to announce that

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that

CARI Blog #2: Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada

Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people are unaware of Canadian role in this industry. However, several medical applications that are used widely today stemmed from Canadian nuclear isotope programs where much

For more information contact us at: